Diagnosis
ALK-positive left lung cancer with an acinar adenocarcinoma component; malignant bilateral pleural effusion (fluid around the lungs); hydropericardium (fluid around the heart); mediastinal lymphadenopathy; and focal lesions in the frontal and parietal lobes of the brain (brain metastases).
Patient:
Male, 39 years old, Belarus
Physician:
Dr. Christian Müller, Director of the Clinic for Internal Oncology, Essen-Mitte Clinic
Patient Questions:
During molecular biological testing of the available tissue blocks, an ALK gene mutation was identified. However, the test results for EGFR and BRAF status were inconclusive due to the insufficient volume of the provided biological sample. What treatment options can you offer in this scenario?
Response from Clinic Director, Dr. Christian Müller:
We have reviewed the provided medical records and imaging at our multidisciplinary tumor board. In this case, we are addressing a metastatic disease process.
The morphological finding confirms non-small cell lung cancer (NSCLC) with metastases to both the lungs and the brain.
- Initial Tumor Stage: cT4 cN3 cM1c (BRA, PUL) — Stage IVB according to the IASLC/UICC classification.
To ensure a comprehensive diagnostic picture, we recommend completing the following staging evaluations:
- Abdominal CT scan
- Bone scintigraphy (skeletal scan)
- Repeat tissue biopsy for molecular genetic analysis
There are indications for palliative systemic therapy aimed at controlling the disease, maintaining quality of life, and alleviating symptoms.
Based on our clinical criteria, the provided molecular pathology results require re-verification for complete confidence. Due to the limited tissue sample, adequate testing for additional markers (such as EGFR or BRAF) could not be completed. Therefore, we recommend a repeat biopsy to obtain sufficient tissue material. This will allow us to confirm the ALK mutation reliably and evaluate other key genetic markers.
Should the patient choose, both the repeat biopsy and all necessary staging studies can be arranged at our clinic in Germany within the shortest possible timeframe.
Follow-up Questions from the Patient:
The ALK gene mutation has now been confirmed by additional molecular testing.
I am currently in Belarus, and given my condition and stage of disease, treatment needs to begin as soon as possible. Visa processing will take time that I simply do not have. Is it possible to start treatment locally to slow disease progression and buy time while the visa is being processed?
In light of this, I would like to know what standard treatment is administered in Germany for confirmed ALK-positive lung cancer? Not starting any therapy now feels far riskier than attempting to control the disease using the data we already have.
Physician’s Response:
For confirmed ALK-positive non-small cell lung cancer, our primary treatment choice is Lorlatinib. This target-specific drug has demonstrated exceptional efficacy in managing and preventing brain metastases, which significantly increases the likelihood of avoiding brain radiation therapy.
Highly effective alternative target therapies include Alectinib and Brigatinib, both of which are standard-of-care treatments for ALK-positive NSCLC.
If these targeted ALK inhibitors are temporarily unavailable in your home country, standard combination chemotherapy with Carboplatin and Pemetrexed can be initiated to contain disease progression while you prepare for travel. Please note that immune checkpoint inhibitors (immunotherapy) are generally ineffective for tumors driven by ALK mutations and are therefore not indicated.
Time is critical in cancer care: The sooner tailored targeted treatment begins, the better the therapeutic outcome.
Contact our medical coordinators today: +491706247020
The clinical case summaries presented on our website are for informational purposes only and do not constitute formal medical advice. All medications and treatment regimens must be prescribed and monitored by a qualified physician.